Celldex to Present 52-Week Barzolvolimab Phase 2 Study Results in Chronic Urticaria at EADV 2024

Celldex Therapeutics, Inc., a clinical-stage biotechnology company, has announced the acceptance of an abstract detailing the results of their Phase 2 clinical trial for barzolvolimab. This study focuses on patients with moderate to severe chronic spontaneous urticaria (CSU) who are unresponsive to antihistamines, including those with biologic-refractory disease. The abstract is set to be presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam from September 25-28, 2024. The presentation will provide insights into the 52-week results of the trial.

The abstract, titled "Barzolvolimab shows profound efficacy and favorable safety over 52 weeks in patients with Chronic Spontaneous Urticaria," will be delivered by Martin Metz, M.D., a Professor of Dermatology and Allergy at Charité - Universitätsmedizin in Berlin. Scheduled in the "Late breaking news" session, the presentation will occur on Wednesday, September 25th, from 16:45 to 17:00 CEST (10:45 – 11:00 am ET).

Additionally, an e-poster (#P3596) titled "Barzolvolimab treatment improves quality of life and urticaria control in patients with chronic spontaneous urticaria (CSU): Results from a Phase 2 trial," will also be available during the EADV Congress. This poster will focus on the 12-week analysis of the trial and can be accessed in the e-poster area and on the online EADV platform.

Celldex Therapeutics is at the forefront of developing transformative therapeutics targeting mast cell biology. The company’s pipeline consists of antibody-based treatments designed to engage the human immune system or directly influence critical pathways to aid patients suffering from severe inflammatory, allergic, autoimmune, and other debilitating diseases.

Barzolvolimab, also known as CDX-0159, is an investigational drug developed by Celldex. The Phase 2 trial's promising results indicate that barzolvolimab not only shows significant efficacy but also maintains a favorable safety profile over a 52-week period in CSU patients who have not found relief from conventional antihistamine treatments. This makes it a potential game-changer for those with biologically refractory CSU.

The upcoming presentation and e-poster at the EADV Congress will provide detailed data on the effectiveness and safety of barzolvolimab. These findings are expected to contribute significantly to the understanding and management of CSU, offering new hope to many patients suffering from this challenging condition.

Celldex's focus on severe diseases through innovative antibody-based therapies underlines its commitment to improving patient outcomes and quality of life. The company's work in mast cell biology and immune system engagement continues to push the boundaries of treatment for various debilitating conditions. As the scientific community gathers in Amsterdam for the EADV Congress, all eyes will be on the groundbreaking work presented by Celldex Therapeutics, marking another milestone in their journey toward transforming patient care in chronic spontaneous urticaria and beyond.